Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 26
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
J Chem Ecol ; 39(2): 253-61, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23314893

RESUMEN

A multiyear effort to identify new natural products was built on a hypothesis that both phytotoxins from plant pathogens and antimicrobial compounds might demonstrate herbicidal activity. The discovery of one such compound, mevalocidin, is described in the current report. Mevalocidin was discovered from static cultures of two unrelated fungal isolates designated Rosellinia DA092917 and Fusarium DA056446. The chemical structure was confirmed by independent synthesis. Mevalocidin demonstrated broad spectrum post-emergence activity on grasses and broadleaves and produced a unique set of visual symptoms on treated plants suggesting a novel mode of action. Mevalocidin was rapidly absorbed in a representative grass and broadleaf plant. Translocation occurred from the treated leaf to other plant parts including roots confirming phloem as well as xylem mobility. By 24 hr after application, over 20 % had been redistributed through-out the plant. Mevalocidin is a unique phytotoxin based on its chemistry, with the uncommon attribute of demonstrating both xylem and phloem mobility in grass and broadleaf plants.


Asunto(s)
Ascomicetos/química , Productos Biológicos/química , Ácidos Carboxílicos/química , Fusarium/química , Herbicidas/química , Fenómenos Fisiológicos de las Plantas , Productos Biológicos/aislamiento & purificación , Productos Biológicos/metabolismo , Transporte Biológico , Ácidos Carboxílicos/aislamiento & purificación , Ácidos Carboxílicos/metabolismo , Herbicidas/aislamiento & purificación , Herbicidas/metabolismo , Floema/metabolismo , Xilema/metabolismo
2.
Pest Manag Sci ; 64(12): 1285-93, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18683908

RESUMEN

BACKGROUND: The demethylation inhibitor (DMI) fungicide myclobutanil can be an effective component of spray programmes designed to control the highly destructive plant pathogen Phakopsora pachyrhizi Syd. & P. Syd., causal agent of Asian soybean rust. Myclobutanil is known from previous studies in grapevines to be xylem mobile. This study investigates the mobility profile of myclobutanil in soybean as an important component of its effective field performance. RESULTS: Over a 12 day period under greenhouse conditions, a constant uptake of myclobutanil from leaflet surfaces into the leaflet tissue was observed. Once in the leaflet, myclobutanil was seen to redistribute throughout the tissue, although no movement out of leaflets occurred owing to a lack of phloem mobility. The ability of myclobutanil to redistribute over distance within the soybean plant was revealed when visualizing movement of the compound to foliage above the point of application on the plant stem. An efficacy bioassay demonstrated that the systemic properties of myclobutanil allow control of disease at a point remote from the initial site of compound application. CONCLUSION: It is suggested that the high degree of xylem systemicity displayed by myclobutanil in soybean foliage is a contributory factor towards its commercial effectiveness for control of Asian soybean rust.


Asunto(s)
Basidiomycota/efectos de los fármacos , Fungicidas Industriales/farmacocinética , Glycine max/metabolismo , Nitrilos/farmacocinética , Hojas de la Planta/metabolismo , Triazoles/farmacocinética , Enfermedades de las Plantas/microbiología , Tallos de la Planta/metabolismo
3.
J Agric Food Chem ; 65(34): 7328-7336, 2017 Aug 30.
Artículo en Inglés | MEDLINE | ID: mdl-28771349

RESUMEN

Green foxtail [Setaria viridis (L) Beauv.] and yellow foxtail [Setaria pumila (Poir.) Roem. & Schult.] are among the most abundant and troublesome annual grass weeds in cereal crops in the Northern Plains of the United States and the Prairie Provinces of Canada. Greenhouse and laboratory experiments were conducted to examine the differential responses of both weed species to foliar applications of the new triazolopyrimidine sulfonamide acetolactate synthase-inhibiting herbicide, pyroxsulam, and to determine the mechanism(s) of differential weed control. Foliar applications of pyroxsulam resulted in >90% control of yellow foxtail at rates between 7.5 and 15 g ai ha-1, whereas the same rates resulted in a reduced efficacy on green foxtail (≤81%). The absorption and translocation of [14C]pyroxsulam in green and yellow foxtail were similar and could not explain the differential whole-plant efficacy. Studies with [14C]pyroxsulam revealed a higher percentage of absorbed pyroxsulam was metabolized into an inactive metabolite in the treated leaf of green foxtail than in the treated leaf of yellow foxtail. Metabolism studies demonstrated that, 48 h after application, 50 and 35% of pyroxsulam in the treated leaf was converted to 5-hydroxy-pyroxsulam in green and yellow foxtail, respectively. The acetolactate synthase (ALS) inhibition assay showed that ALS extracted from green foxtail was more tolerant to pyroxsulam than the enzyme extracted from yellow foxtail was. The in vitro ALS assay showed IC50 values of 8.39 and 0.26 µM pyroxsulam for green and yellow foxtail, respectively. The ALS genes from both green and yellow foxtail were sequenced and revealed amino acid differences; however, the changes are not associated with known resistance-inducing mutations. The differential control of green and yellow foxtail following foliar applications of pyroxsulam was attributed to differences in both metabolism and ALS sensitivity.


Asunto(s)
Herbicidas/farmacología , Setaria (Planta)/efectos de los fármacos , Acetolactato Sintasa/antagonistas & inhibidores , Acetolactato Sintasa/genética , Acetolactato Sintasa/metabolismo , Inhibidores Enzimáticos/farmacología , Hojas de la Planta/efectos de los fármacos , Hojas de la Planta/enzimología , Hojas de la Planta/genética , Proteínas de Plantas/antagonistas & inhibidores , Proteínas de Plantas/genética , Proteínas de Plantas/metabolismo , Pirimidinas/farmacología , Setaria (Planta)/enzimología , Setaria (Planta)/genética , Sulfonamidas/farmacología
4.
Pest Manag Sci ; 73(4): 752-760, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27414472

RESUMEN

BACKGROUND: The adrenergic mode of action was investigated for the development of potential new insecticides. Clonidine-related analogs were tested against Myzus persicae (Sulzer) and Bemisia tabaci (Gennadius). Clonidine analogs lack translation owing to a possible vacuole-trapping mechanism. Physical property modulation via a prodrug approach was attempted to overcome this mechanism. RESULTS: Clonidine showed insecticidal activity against M. persicae and B. tabaci. A prodrug of a known open-chain analog of clonidine was developed. While the prodrug had decreased pKa and increased lipophilicity and displayed good activity against M. persicae B. tabaci, the activity did not translate to cotton. Metabolic studies showed that the prodrug was quickly metabolized to the parent compound, and was further metabolized to a known vacuole-trapped oxazoline analog. CONCLUSIONS: Adrenergic active compounds, such as clonidine analogs, show potential as insecticides; however, a designed prodrug approach did not overcome the lack of translation in this case. Studies confirmed that the synthesized prodrug analog metabolized in planta to the proposed vacuole-trapped compound. One possible explanation for the failure of this approach is that the rate of metabolism and vacuole trapping is faster than translaminar flow, and therefore the released pesticide is not biologically available to the target organism. © 2016 Society of Chemical Industry.


Asunto(s)
Clonidina/análogos & derivados , Clonidina/farmacología , Hemípteros/efectos de los fármacos , Insecticidas/farmacología , Animales , Áfidos/efectos de los fármacos , Áfidos/crecimiento & desarrollo , Hemípteros/crecimiento & desarrollo , Ninfa/efectos de los fármacos , Hojas de la Planta/fisiología , Pupa/efectos de los fármacos
5.
Int J Radiat Oncol Biol Phys ; 65(1): 78-83, 2006 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-16563657

RESUMEN

PURPOSE: To examine the effect of salvage radiotherapy (RT) plus 2-year androgen suppression (AS) on quality of life (QOL). METHODS AND MATERIALS: A total of 74 patients with biopsy-proven local recurrence or PSA relapse after radical prostatectomy were treated with salvage RT plus 2-year AS, as per a phase II study. Quality of life was prospectively assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-Item Version 3.0 with the added prostate cancer-specific module at baseline and predefined follow-up visits. RESULTS: Patients experienced a significant increase in bowel dysfunction (23%) by the end of RT (p < 0.0001). This bowel dysfunction improved after RT but remained slightly elevated (5-10%) throughout the 2-year AS period. This extent of residual bowel dysfunction would be considered of minimal clinical importance. A similar, but less pronounced, pattern of change did occur for urinary dysfunction. Erectile function showed no change during RT, but had an abrupt decline (10%) with initiation of AS that was of moderate clinical significance (p < 0.01). None of the other QOL domains demonstrated a persistent, significant change from baseline that would be considered of major clinical significance. CONCLUSION: The combined treatment with salvage RT plus 2-year AS had relatively minor long-term effects on QOL.


Asunto(s)
Recurrencia Local de Neoplasia/tratamiento farmacológico , Recurrencia Local de Neoplasia/radioterapia , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/radioterapia , Calidad de Vida , Terapia Recuperativa/métodos , Anciano , Antagonistas de Andrógenos/uso terapéutico , Antineoplásicos Hormonales/uso terapéutico , Diarrea/etiología , Humanos , Enfermedades Intestinales/etiología , Masculino , Recurrencia Local de Neoplasia/sangre , Erección Peniana , Antígeno Prostático Específico/sangre , Prostatectomía , Neoplasias de la Próstata/sangre , Neoplasias de la Próstata/cirugía , Trastornos Urinarios/etiología
6.
Pest Manag Sci ; 62(4): 316-24, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16506146

RESUMEN

Florasulam is a triazolopyrimidine sulfonanilide post-emergence broadleaf herbicide for use in wheat (Triticum aestivum L.). The selectivity of florasulam to wheat has been determined to be related primarily to a differential rate of metabolism between wheat with a half-life of 2.4 h and broadleaf weeds with half-lives ranging from 19 to >48 h. To a lesser extent, selectivity, at least for the broadleaf weed cleavers (Galium aparine L.), involves uptake differences. Rate of metabolism data were generated using greenhouse-grown plants injected with radiolabelled florasulam and subsequent extraction and processing by high-performance liquid chromatography (HPLC). Structures of metabolites were determined by isolation for nuclear magnetic resonance and liquid chromatography/mass spectrometry. Wheat plants metabolised florasulam by hydroxylation of the aniline ring para to the nitrogen, followed by conjugation to glucose. Metabolism by broadleaf weeds was so slow that isolation of metabolite was not possible, but comparison of HPLC data suggested hydroxylation as the major pathway.


Asunto(s)
Herbicidas/metabolismo , Pirimidinas/metabolismo , Sulfonamidas/metabolismo , Triticum/metabolismo , Transporte Biológico , Galium/metabolismo , Herbicidas/química , Herbicidas/farmacocinética , Lamiaceae/metabolismo , Estructura Molecular , Hojas de la Planta/metabolismo , Raíces de Plantas/metabolismo , Polygonum/metabolismo , Pirimidinas/química , Pirimidinas/farmacocinética , Sulfonamidas/química , Sulfonamidas/farmacocinética
7.
Int J Radiat Oncol Biol Phys ; 62(2): 418-25, 2005 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-15890583

RESUMEN

PURPOSE: The objective of the study was to access toxicities of delivering a hypofractionated intensity-modulated radiotherapy (IMRT) boost with individualized intrafraction planning target volume (PTV) margins and daily online correction for prostate position. METHODS AND MATERIALS: Phase I involved delivering 42 Gy in 21 fractions using three-dimensional conformal radiotherapy, followed by a Phase II IMRT boost of 30 Gy in 10 fractions. Digital fluoroscopy was used to measure respiratory-induced motion of implanted fiducial markers within the prostate. Electronic portal images were taken of fiducial marker positions before and after each fraction of radiotherapy during the first 9 days of treatment to calculate intrafraction motion. A uniform 10-mm PTV margin was used for the first phase of treatment. PTV margins for Phase II were patient-specific and were calculated from the respiratory and intrafraction motion data obtained from Phase I. The IMRT boost was delivered with daily online correction of fiducial marker position. Acute toxicity was measured using National Cancer Institute Common Toxicity Criteria, version 2.0. RESULTS: In 33 patients who had completed treatment, the average PTV margin used during the hypofractionated IMRT boost was 3 mm in the lateral direction, 3 mm in the superior-inferior direction, and 4 mm in the anteroposterior direction. No patients developed acute Grade 3 rectal toxicity. Three patients developed acute Grade 3 urinary frequency and urgency. CONCLUSIONS: PTV margins can be reduced significantly with daily online correction of prostate position. Delivering a hypofractionated boost with this high-precision IMRT technique resulted in acceptable acute toxicity.


Asunto(s)
Movimiento , Próstata , Neoplasias de la Próstata/radioterapia , Radioterapia Conformacional/métodos , Anciano , Anciano de 80 o más Años , Fraccionamiento de la Dosis de Radiación , Fluoroscopía/métodos , Humanos , Masculino , Persona de Mediana Edad , Próstata/diagnóstico por imagen , Neoplasias de la Próstata/diagnóstico por imagen , Respiración , Vesículas Seminales/diagnóstico por imagen , Trastornos Urinarios/etiología
8.
Int J Radiat Oncol Biol Phys ; 62(3): 719-24, 2005 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-15936551

RESUMEN

PURPOSE: To examine the effect of 2-year androgen suppression (AS) on the pattern and extent of hemoglobin (Hb) change. METHODS AND MATERIALS: The basis of this report was a Phase II study evaluating a combined treatment of salvage radiotherapy plus 2-year AS for a rising prostate-specific antigen level after surgery. Patients had laboratory tests performed, including Hb and serum testosterone, and answered a quality-of-life questionnaire (European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire 30 item) at regular intervals during the AS and post-AS period. The pattern and extent of the change in Hb was analyzed in relation to the testosterone level. The clinical significance of the Hb change was evaluated with a correlation analysis between Hb and the three specific domains of the questionnaire (Global Health Status, Physical Functioning, and Fatigue). RESULTS: Of a total of 74 accrued patients, 69 were identified as eligible for this report. The median patient age was 70 years. The median follow-up was 38.6 months. The mean Hb was 150.7 g/L at baseline and declined with radiotherapy by 5.9 g/L. The maximal Hb drop during AS was 16.0 g/L (p <0.0001), occurring at 16 months after the initiation of AS. Hb recovery in the post-AS period was slow. The decline and recovery of the mean Hb and hematocrit followed that of testosterone. The three quality-of-life domains did not show any significant correlation with the change in Hb. CONCLUSION: Two-year AS resulted in a statistically significant drop in the mean Hb, but had no clinically apparent adverse effect. The pattern of Hb change was similar to that of testosterone change.


Asunto(s)
Antineoplásicos Hormonales/uso terapéutico , Buserelina/uso terapéutico , Hemoglobinas/metabolismo , Neoplasias de la Próstata/sangre , Neoplasias de la Próstata/terapia , Terapia Recuperativa , Anciano , Fatiga , Estado de Salud , Hematócrito , Humanos , Masculino , Prostatectomía , Calidad de Vida , Testosterona/sangre
9.
Int J Radiat Oncol Biol Phys ; 61(5): 1473-81, 2005 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-15817353

RESUMEN

PURPOSE: To determine the proportion of patients undergoing palliative radiotherapy (RT) for bone pain who would like to participate in the decision-making process, and to determine their choice of palliative RT regimen (2000 cGy in five fractions vs. 800 cGy in one fraction) for painful bone metastases. METHODS AND MATERIALS: Eligible patients were approached and all patients agreeing to participate provided written informed consent. Patients' decisional preferences were studied using a five-statement preference instrument. A decision board was used to help patients decide their preferred palliative RT regimen. Factors influencing patients' choices were studied using a visual analog scale. RESULTS: A total of 101 patients were enrolled in the study (55 women and 46 men). The preferences for decision-making were as follows: 30 active, 47 collaborative, and 24 passive. Most (55 [76%] of 72) patients favored one fraction of palliative RT (95% confidence interval, 65-86%). Patients were more likely to select the 800 cGy in one fraction because of the convenience of the treatment plan (odds ratio, 1.024; 95% confidence interval, 1.004-1044) but were less likely to choose it because of the chance of bone fracture (odds ratio, 0.973; 95% confidence interval, 0.947-1.000) compared with 2000 cGy in five fractions. CONCLUSION: Most participating patients preferred to decide either by themselves or with the radiation oncologists which treatment option they preferred. An 800-cGy-in-one-fraction regimen was favored, independent of the treated site. The convenience of the treatment plan and the likelihood of bone fracture were the most important factors influencing patients' choice.


Asunto(s)
Neoplasias Óseas/radioterapia , Neoplasias Óseas/secundario , Cuidados Paliativos/métodos , Participación del Paciente , Satisfacción del Paciente , Anciano , Neoplasias Óseas/psicología , Intervalos de Confianza , Toma de Decisiones , Fraccionamiento de la Dosis de Radiación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Cuidados Paliativos/psicología , Encuestas y Cuestionarios
10.
Radiother Oncol ; 74(2): 163-7, 2005 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-15734204

RESUMEN

BACKGROUND AND PURPOSE: To assess the efficacy of salvage radiotherapy (RT) for biopsy confirmed or clinically palpable local recurrence of prostate adenocarcinoma after radical prostatectomy (RP). PATIENTS AND METHODS: We retrospectively analyzed 44 patients treated with salvage RT for biopsy confirmed or clinically palpable local recurrence between 1991 and 2000. Thirty-six had positive biopsy for local recurrence and the rest without histological confirmation had clinically palpable disease. All had rising PSA at the time of RT (median: 3.7). Median interval from RP to RT was 2.6 years. Thirty-six received salvage RT alone, while eight had a short course (<4 months) of androgen ablation prior to RT. RT doses were 60-66Gy in 30-33 fractions. Freedom from PSA failure was defined as the maintenance of PSA

Asunto(s)
Adenocarcinoma/radioterapia , Adenocarcinoma/cirugía , Recurrencia Local de Neoplasia/radioterapia , Prostatectomía , Neoplasias de la Próstata/radioterapia , Neoplasias de la Próstata/cirugía , Terapia Recuperativa , Adenocarcinoma/patología , Anciano , Biopsia , Supervivencia sin Enfermedad , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Neoplasias de la Próstata/patología , Estudios Retrospectivos , Resultado del Tratamiento
11.
Can J Urol ; 12(1): 2547-52, 2005 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-15777493

RESUMEN

PURPOSE: To examine the change of hemoglobin in relation to testosterone level in non-metastatic prostate cancer patients receiving 2-year androgen suppression. METHODS AND MATERIALS: A cohort of 72 patients, as participants of a phase II study, were treated with adjuvant radiotherapy plus 2-year androgen suppression after surgery to reduce the risk of relapse. Patients had laboratory tests including hemoglobin (Hb) and testosterone, and a quality of life questionnaire at regular intervals during the androgen suppression and post-androgen suppression period. The pattern of the change in Hb was evaluated in relation to testosterone level. The clinical significance of Hb change was assessed with a correlation analysis between Hb and the three domains of the questionnaire (global health status, physical functioning, and fatigue). RESULTS: Median age was 64.2 years. Median follow-up was 37 months. Mean Hb at the baseline was 148.4 g/L. It declined slightly with radiotherapy by 2.2 g/L. Maximal Hb decline during androgen suppression was 10.5 g/L (p < 0.0001), occurring at 24 months after the initiation of androgen suppression. In most patients, Hb decline was < 20 g/L. In the post-androgen suppression period, the recovery of Hb was slow and followed that of testosterone. The three quality of life domains did not show any significant correlation with the change in Hb. CONCLUSION: The decline and recovery of Hb was closely related to that of testosterone. Two-year androgen suppression resulted in a statistically significant decline of Hb, which had, however, no clinically apparent adverse effect on the three quality of life domains.


Asunto(s)
Anemia/etiología , Antineoplásicos Hormonales/uso terapéutico , Hemoglobinas/metabolismo , Neoplasias de la Próstata/sangre , Neoplasias de la Próstata/terapia , Anciano , Antagonistas de Andrógenos/uso terapéutico , Buserelina/uso terapéutico , Ensayos Clínicos Fase II como Asunto , Humanos , Imidazolidinas/uso terapéutico , Masculino , Persona de Mediana Edad , Radioterapia Adyuvante , Perfil de Impacto de Enfermedad , Testosterona/sangre
12.
Int J Radiat Oncol Biol Phys ; 53(2): 269-76, 2002 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-12023129

RESUMEN

PURPOSE: To determine the efficacy of external beam radiotherapy (RT) as salvage treatment for prostate-specific antigen (PSA) failure or local recurrence after radical prostatectomy. METHODS AND MATERIALS: Between 1991 and 1997, 98 patients underwent salvage RT to the prostatic bed at the Toronto Sunnybrook Regional Cancer Centre for PSA failure or local recurrence after radical prostatectomy. Thirty-six patients were treated for persistently detectable postoperative PSA levels (Group A), 26 for a delayed PSA rise (Group B), and 36 for palpable and/or biopsy-proven local recurrence (Group C). None had clinically apparent distant metastasis at the time of salvage RT. Freedom from PSA failure was defined as the maintenance of PSA

Asunto(s)
Recurrencia Local de Neoplasia/radioterapia , Antígeno Prostático Específico/sangre , Neoplasias de la Próstata/radioterapia , Terapia Recuperativa/métodos , Anciano , Antagonistas de Andrógenos/uso terapéutico , Quimioterapia Adyuvante , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/sangre , Prostatectomía , Neoplasias de la Próstata/sangre , Neoplasias de la Próstata/cirugía , Análisis de Regresión , Estudios Retrospectivos , Análisis de Supervivencia
13.
Int J Radiat Oncol Biol Phys ; 52(3): 674-80, 2002 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-11849789

RESUMEN

PURPOSE: To evaluate the efficacy of postoperative adjuvant radiotherapy (RT) for positive resection margin and/or pathologic T3 (pT3) adenocarcinoma of the prostate with undetectable postoperative prostate-specific antigen (PSA) levels. METHODS AND MATERIALS: We retrospectively analyzed 125 patients with a positive resection margin and/or pT3 adenocarcinoma of the prostate who had undetectable postoperative serum PSA levels after radical prostatectomy. Seventy-three patients received postoperative adjuvant RT and 52 did not. Follow-up ranged from 1.5 to 12.0 years (median 4.2 for the irradiated group and 4.9 for the nonirradiated group). PSA outcome was available for all patients. Freedom from failure was defined as the maintenance of a serum PSA level of < or =0.2 ng/mL, as well as the absence of clinical local recurrence and distant metastasis. RESULTS: No difference was found in the 5-year actuarial overall survival between the irradiated and nonirradiated group (94% vs. 95%). However, patients receiving adjuvant RT had a statistically superior 5-year actuarial relapse-free rate, including freedom from PSA failure, compared with those treated with surgery alone (88% vs. 65%, p = 0.0013). In the irradiated group, 8 patients had relapse with PSA failure alone. None had local or distant recurrence. In the nonirradiated group, 15, 1, and 2 had PSA failure, local recurrence, and distant metastasis, respectively. On Cox regression analysis, pre-radical prostatectomy PSA level and adjuvant RT were statistically significant predictive factors for relapse, and Gleason score, extracapsular invasion, and resection margin status were not. There was a suggestion that seminal vesicle invasion was associated with an increased risk of relapse. The morbidity of postoperative adjuvant RT was acceptable, with only 2 patients developing Radiation Therapy Oncology Group Grade 3 genitourinary complications. Adjuvant RT had a minimal adverse effect on urinary continence and did not cause serious gastrointestinal toxicity. CONCLUSION: Postoperative adjuvant RT was associated with a lower risk of relapse, including freedom from PSA failure, compared with observation alone for pT3 and/or margin-positive disease with undetectable postoperative PSA levels. This was accomplished with a minimal risk of serious RT morbidity.


Asunto(s)
Adenocarcinoma/radioterapia , Antígeno Prostático Específico/sangre , Neoplasias de la Próstata/radioterapia , Adenocarcinoma/sangre , Adenocarcinoma/patología , Adenocarcinoma/cirugía , Adulto , Anciano , Disfunción Eréctil/etiología , Humanos , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Neoplasia Residual , Prostatectomía , Neoplasias de la Próstata/sangre , Neoplasias de la Próstata/patología , Neoplasias de la Próstata/cirugía , Radioterapia Adyuvante , Análisis de Regresión , Estudios Retrospectivos , Análisis de Supervivencia , Incontinencia Urinaria/etiología
14.
Int J Radiat Oncol Biol Phys ; 53(2): 290-6, 2002 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-12023132

RESUMEN

PURPOSE: To quantify the effect of radiotherapy (RT) on urodynamics at 18 months post-therapy, using urodynamic study, in prostate cancer patients undergoing definitive external beam RT. METHODS AND MATERIALS: A total of 17 patients with clinically localized prostate cancer were accrued into a single-arm prospective study. Fifteen of 17 patients completed scheduled multichannel video-urodynamic study at baseline as well as 3 and 18 months after RT. Baseline quantitative urodynamic parameters were compared with those at 18 months post-RT to assess the nature and extent of urodynamic change brought about by RT. These quantitative changes were further correlated to the change in self-assessed qualitative urinary function measured by International Prostate Symptom Score (IPSS), Quality of Life assessment index (QoL), and urinary functional inquiry. RESULTS: The statistically significant quantitative changes detected by the urodynamic study at 18 months post-RT were decrease in bladder capacity and bladder volume at first sensation in both the supine and upright position, and reduction in bladder volume at desire to void in the supine position. In our cohort, the mean reduction in bladder capacity was 100 mL in the supine position and 54 mL in the upright position. No statistically significant change was observed with regard to pressure, maximum flow rate, voided volume, or postvoid residual volume. Furthermore, there was no statistically significant change in bladder compliance, bladder instability, or bladder outlet obstruction. No statistically significant change in self-assessed qualitative urological function was observed between baseline and 18 months post-RT, measured by the 3 parameters (IPSS, QoL, and urinary frequency over 24 h). CONCLUSIONS: This is the first quantitative study that prospectively evaluated the effect of RT on urodynamics in prostate cancer patients receiving definitive RT. The statistically significant changes at 18 months post-RT were reduction in bladder capacity, reduction in bladder volume at first sensation, and decrease in bladder volume at desire to void. Despite the decrease in these parameters, there was no statistically significant adverse effect of RT on bladder compliance, bladder stability, or bladder outlet flow. This observation corresponded well with no significant change in IPSS, QoL, or urinary frequency over 24 h. Furthermore, these results confirm the notion that most prostate cancer patients generally tolerate RT very well.


Asunto(s)
Neoplasias de la Próstata/radioterapia , Vejiga Urinaria/efectos de la radiación , Anciano , Humanos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Postura , Estudios Prospectivos , Neoplasias de la Próstata/fisiopatología , Calidad de Vida , Factores de Tiempo , Trastornos Urinarios/fisiopatología , Orina , Urodinámica/efectos de la radiación
15.
Clin Biochem ; 35(6): 471-5, 2002 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-12413608

RESUMEN

OBJECTIVE: To determine the intraindividual variation of prostate-specific antigen (PSA) isoforms in prostate cancer patients managed conservatively with watchful observation. METHODS: Patients with favorable clinical parameters (stage T1b-T2b N0 M0, Gleason score

Asunto(s)
Antígeno Prostático Específico/análisis , Antígeno Prostático Específico/metabolismo , Neoplasias de la Próstata/metabolismo , Estudios de Cohortes , Progresión de la Enfermedad , Humanos , Masculino , Estadificación de Neoplasias , Neoplasias de la Próstata/clasificación , Neoplasias de la Próstata/patología , Sensibilidad y Especificidad , Factores de Tiempo
16.
Can J Urol ; 9(2): 1479-85, 2002 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12010592

RESUMEN

OBJECTIVE: To evaluate practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States. MATERIALS AND METHODS: Survey among radiation oncologists treating genitourinary (GU) tumors in Canada and the RTOG GU committee members in the United States between January and March 2001. RESULTS: Response rate was 78% (73/93) in Canada and 67% (24/36) in the United States. Eighty-four percent described their clinical practice as a university affiliated teaching center, and 16% as community-based or private practice. Sixty-two percent, 31% and 7% would manage 1-5, 6-10 and > oe = 11 cases per year respectively. Almost all would perform chest x-ray (99%) and CT scan of abdomen and pelvis (100%) as staging investigation following radical inguinal orchiectomy. Forty percent also arranged CT scan of chest, while only 18% routinely obtained lymphangiogram. Seventy-eight percent offered surveillance as a management option and estimated that 20% (median) of patients would choose surveillance in their practice. Among four management options: (1. surveillance, 2. radiotherapy (RT) to the para-aortic region, 3. RT to the para-aortic and ipsilateral pelvis ('dog-leg'), 4. single-agent chemotherapy), the order of first preference was option 1 (44%), 2 (42%), and 3 (14%) for patients who wish to preserve fertility. When fertility was not a major concern, it was option 2 (43%), 3 (39%), and 1 (17%). The commonest dose-fractionation schedule was 25 Gy/20 fractions (68%). Others included 25 Gy/15 f (15%), and 25.5 Gy/17 f (4%). Forty-five percent chose the para-aortic region, while 53% used the 'dog-leg' as RT volume. Twenty-nine percent reduced RT volume from the 'dog-leg' to the para-aortic region as the result of MRC Phase III study published in 1999. CONCLUSION: There are significant variations in the practice pattern of the management of stage I seminoma of testis among radiation oncologists in Canada and a selected group in the United States.


Asunto(s)
Pautas de la Práctica en Medicina/estadística & datos numéricos , Seminoma/terapia , Neoplasias Testiculares/terapia , Canadá , Recolección de Datos/métodos , Fraccionamiento de la Dosis de Radiación , Humanos , Masculino , Estadificación de Neoplasias , Oncología por Radiación , Radioterapia Adyuvante , Seminoma/patología , Encuestas y Cuestionarios , Neoplasias Testiculares/patología , Estados Unidos
17.
JAMA ; 292(11): 1317-25, 2004 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-15367553

RESUMEN

CONTEXT: Current recommendations for women who have a BRCA1 or BRCA2 mutation are to undergo breast surveillance from age 25 years onward with mammography annually and clinical breast examination (CBE) every 6 months; however, many tumors are detected at a relatively advanced stage. Magnetic resonance imaging (MRI) and ultrasound may improve the ability to detect breast cancer at an early stage. OBJECTIVE: To compare the sensitivity and specificity of 4 methods of breast cancer surveillance (mammography, ultrasound, MRI, and CBE) in women with hereditary susceptibility to breast cancer due to a BRCA1 or BRCA2 mutation. DESIGN, SETTING, AND PARTICIPANTS: A surveillance study of 236 Canadian women aged 25 to 65 years with BRCA1 or BRCA2 mutations who underwent 1 to 3 annual screening examinations, consisting of MRI, mammography, and ultrasound at a single tertiary care teaching hospital between November 3, 1997, and March 31, 2003. On the day of imaging and at 6-month intervals, CBE was performed. MAIN OUTCOME MEASURES: Sensitivity and specificity of each of the 4 surveillance modalities, and sensitivity of all 4 screening modalities vs mammography and CBE. RESULTS: Each imaging modality was read independently by a radiologist and scored on a 5-point Breast Imaging Reporting and Data System scale. All lesions with a score of 4 or 5 (suspicious or highly suspicious for malignancy) were biopsied. There were 22 cancers detected (16 invasive and 6 ductal carcinoma in situ). Of these, 17 (77%) were detected by MRI vs 8 (36%) by mammography, 7 (33%) by ultrasound, and 2 (9.1%) by CBE. The sensitivity and specificity (based on biopsy rates) were 77% and 95.4% for MRI, 36% and 99.8% for mammography, 33% and 96% for ultrasound, and 9.1% and 99.3% for CBE, respectively. There was 1 interval cancer. All 4 screening modalities combined had a sensitivity of 95% vs 45% for mammography and CBE combined. CONCLUSIONS: In BRCA1 and BRCA2 mutation carriers, MRI is more sensitive for detecting breast cancers than mammography, ultrasound, or CBE alone. Whether surveillance regimens that include MRI will reduce mortality from breast cancer in high-risk women requires further investigation.


Asunto(s)
Neoplasias de la Mama/diagnóstico , Neoplasias de la Mama/genética , Genes BRCA1 , Genes BRCA2 , Adulto , Biopsia , Reacciones Falso Positivas , Femenino , Predisposición Genética a la Enfermedad , Humanos , Imagen por Resonancia Magnética , Mamografía , Persona de Mediana Edad , Mutación , Examen Físico , Sensibilidad y Especificidad , Ultrasonografía Mamaria
18.
Funct Plant Biol ; 41(6): 598-608, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-32481016

RESUMEN

Due to evolved resistance and environmental regulations, there is a particular need in the agricultural market for a new graminicide. An essential requirement of a novel, foliar applied graminicide is sufficient phloem mobility in the plant to reach meristematic tissues for the expression of activity leading to the desired control of unwanted vegetative growth. A robust and reliable phloem bioassay utilising a monocot species is highly desirable for early stage experimental compounds. Vascular tissues and translocation patterns of organic compounds in purple false brome (Brachypodium distachyon L. P. Beauv.), a model organism for temperate grasses, were studied and compared with those of wheat (Triticum aestivum L.). Microscopic studies with tracer dyes were used to determine if B. distachyon has a xylem discontinuity between the developing seed and the rachilla xylem, the same as found in T. aestivum. Based on 14C-radiolabelled and non-radiolabelled studies using known xylem and phloem mobile pesticidal compounds, there was a significant difference in the amount of the xylem mobile compounds in the chaff and stem as compared with the phloem mobile compounds found in the grain. The findings described in this report show a clear evidence of xylem discontinuity in B. distachyon, and provide a novel system for a rapid screening of phloem mobility of herbicides in monocot species.

19.
Pest Manag Sci ; 67(3): 279-86, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21104793

RESUMEN

BACKGROUND: Wheat shows selectivity to pyroxsulam, a new broad-spectrum herbicide with high activity on blackgrass. Studies were performed to establish whether uptake, translocation or metabolism were responsible for the differential activity in wheat compared with blackgrass. In addition, the effect of the safener cloquintocet-mexyl on metabolism was evaluated in wheat and blackgrass shoots. RESULTS: Root uptake of pyroxsulam in blackgrass was significantly higher than in wheat, suggesting a possible activity enhancement in blackgrass owing to root uptake. Translocation to foliage from root uptake as well as translocation out of treated foliage following foliar applications was low in wheat compared with blackgrass, likely owing to the rapid metabolism of pyroxsulam in wheat. Wheat metabolized pyroxsulam significantly faster than blackgrass to the less active O-dealkylation product. Wheat shoots metabolized pyroxsulam faster when the safener cloquintocet-mexyl was present, but cloquintocet-mexyl did not increase the rate of metabolism in blackgrass. CONCLUSIONS: The selectivity of pyroxsulam to wheat relative to blackgrass was connected primarily with differences in the rate of metabolism and generation of an inactive metabolite. Metabolism in wheat restricted subsequent movement of radioactivity out of the treated leaf. The rapid metabolism in wheat was increased by the addition of cloquintocet-mexyl.


Asunto(s)
Poaceae/metabolismo , Sulfonamidas/metabolismo , Triticum/metabolismo , Transporte Biológico , Herbicidas/metabolismo , Herbicidas/farmacocinética , Hojas de la Planta/metabolismo , Raíces de Plantas/metabolismo , Quinolinas/metabolismo , Sulfonamidas/farmacocinética
20.
J Agric Food Chem ; 59(7): 2950-7, 2011 Apr 13.
Artículo en Inglés | MEDLINE | ID: mdl-21105655

RESUMEN

The discovery of sulfoxaflor [N-[methyloxido[1-[6-(trifluoromethyl)-3-pyridinyl]ethyl]-λ(4)-sulfanylidene] cyanamide] resulted from an investigation of the sulfoximine functional group as a novel bioactive scaffold for insecticidal activity and a subsequent extensive structure-activity relationship study. Sulfoxaflor, the first product from this new class (the sulfoximines) of insect control agents, exhibits broad-spectrum efficacy against many sap-feeding insect pests, including aphids, whiteflies, hoppers, and Lygus, with levels of activity that are comparable to those of other classes of insecticides targeting sap-feeding insects, including the neonicotinoids. However, no cross-resistance has been observed between sulfoxaflor and neonicotinoids such as imidacloprid, apparently the result of differences in susceptibility to oxidative metabolism. Available data are consistent with sulfoxaflor acting via the insect nicotinic receptor in a complex manner. These observations reflect the unique structure of the sulfoximines compared with neonicotinoids.


Asunto(s)
Insecticidas/química , Piridinas/química , Compuestos de Azufre/química , Animales , Áfidos , Hemípteros , Imidazoles , Insectos , Resistencia a los Insecticidas , Neonicotinoides , Nitrocompuestos , Receptores Nicotínicos , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA